E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated | |
E.1.1.1 | Medical condition in easily understood language |
Thrombocytopenia induced by chemotherapy in glioblastomas. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10043559 |
E.1.2 | Term | Thrombocytopenia toxic |
E.1.2 | System Organ Class | 100000004851 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018336 |
E.1.2 | Term | Glioblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the incidence of completed chemotherapy cycles |
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the safety of Romiplostim in treating Chemotherapy Induced Thrombocytopenia (CIT) in newly diagnosed glioblastoma patients receiving myelosuppressive chemotherapy by Temozolomide (TMZ).
• To determine the incidence of delayed chemotherapy cycles and the incidence of chemotherapy cycles with dose reduction due to severe TP.
• To describe the incidence of TP resolution during Romiplostim treatment period.
• To determine the incidence of platelets transfusion for TP during Romiplostim treatment.
• To describe the adverse events during Romiplostim and Temozolomide combined treatment.
• To determine the 6 months Progression Free Survival.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Histological proof of newly diagnosed glioblastoma,
• Age: 18 and older,
• Information to patient and signed consent form,
• Indication for a « Stupp » protocol (cerebral focal radiotherapy and concomitant TMZ followed by adjuvant TMZ – 6 cycles),
• Patient with grade 3 or 4 TP during Temozolomide chemotherapy, regardless of when the onset of TP was: after completion of concomitant RT/CT, before adjuvant CT or during adjuvant CT and only if a minimum of 2 cycles are still planned,
• Normal initial platelets count (> 100 000/mm3) before the start of Temozolomide during the RT/CT concomitant phase,
• Adequate haematological, renal, hepatic function at the time of inclusion visit,
• ECOG PS 0-2 (patients unable to walk because of a paralysis and who are up in a wheel chair will be considered as ambulatory for the evaluation of the ECOG performance status),
• Life expectancy > 2 months,
• Patients covered by the French Health Insurance System,
• Negative pregnancy test at the time of inclusion visit,
• If required, effective contraception respecting criteria of CPMP/ICH/286/95 (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner).
|
|
E.4 | Principal exclusion criteria |
• Concomitant radiotherapy (Romiplostim will be started after the completion of the RT/CT concomitant phase),
• Other malignancies (prior hx malignancies),
• Any anterior systemic chemotherapy,
• Any known coagulation disease or known haematological disease even if resolved. Known hypercoagulate state (e.g., factor V Leiden, protein C defiency, protein S deficiency, PT 20201, antiphospholipid antibody syndrome…),
• Prior Romiplostim exposure or prior exposure to other TPO mimetics,
• History of thromboembolic disease < 6 months. Treatment with anticoagulant such as Heparin or antivitamin K (LMWH as prophylactic treatment is authorized),
• Any other hemato-toxicity (anemia, neutropenia) requiring EPO or GCSF,
• Other causes of Temozolomide interruption (non haematological toxicities),
• Known hypersensitivity to any E-coli derived product,
• Participation to any other study during the last 30 days,
• Refusal to give written informed consent,
• Pregnancy or nursing,
• For all men and women of childbearing potential: Refusal or inability to use effective means of contraception,
• Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial,
• Persons protected by a legal regime (guardianship, trusteeship),
• Patients in emergency situations,
• Patients kept in detention. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Proportion of patients receiving 100% of the planned TMZ dosage in the whole Stupp protocol. The primary endpoint will consider dose reduction and dose delay. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Incidence of serious adverse events according to CTCAE 4.0 criteria.
• Incidence of chemotherapy cycles with dose reduction and reasons for dose reduction, incidence of postponed cycles of chemotherapy, reasons for delay and number of delayed days.
• Number and percentage of patients with TP of grade 3 or grade 4 after receiving Romiplostim.
• Number and percentage of patients receiving platelets transfusion for TP.
• Incidence and type of adverse events linked to TP episodes during Romiplostim and Temozolomide combined treatment.
• 6 months Progression Free Survival: The progression will be defined according to the RANO criteria. The progression will not be reported as an adverse event if it is related to the disease.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | 15 |